ESC 23: Hot Line & Late-breaking Science Video Collection
-
4m 1s
-
3m 59sPart 4 | Session 7 HEART-FID: Ferric Carboxymaltose in HF with Iron Deficiency
-
4m 49sPart 4 | Session 8 SurHyb Trial: Hybrid Ablation in Persistent Atrial Fibrillation
-
4m 41s
-
4m 12sPart 4 | Session 10 ILUMIEN IV: OCT Vs Angiography
-
5m 20sPart 4 | Session 11 ReDS-SAFE HF: ReDS-Guided Strategy in Heart Failure
-
5m 23sPart 4 | Session 12 MULTISTARS AMI: Immediate Vs Staged PCI in STEMI and MVD
-
6m 3sPart 4 | Session 13 OCT Vs IVUS Vs Angiography Guidance
-
4m 5sPart 4 | Session 14 OCTOBER: OCT-Guided or Angiography-Guided PCI in Complex Bifurcation Lesions
-
2m 55sPart 4 | Session 15 DANPACE II: Reducing Atrial Pacing in Sinus Node Disease
-
6m 43sPart 4 | Session 16 COP-AF: Colchicine for Perioperative AF
-
4m 33sPart 4 | Session 17 CASTLE-HTx: Catheter Ablation for AF in Pts with Heart Failure
-
4m 53sPart 4 | Session 18 OCTIVUS: OCT Vs IVUS-Guided Percutaneous Coronary Intervention
-
4m 56sPart 4 | Session 19 PUSH-AHF: Natriuresis-Guided Therapy in Acute Heart Failure
-
4m 16s
-
4m 8sPart 4 | Session 21 ONCO DVT: Optimal Duration of DOAC Therapy for IDDVT Patients with Cancer
-
4m 39sPart 4 | Session 22 ATTRibute-CM Trial
-
5m 21sPart 4 | Session 23 RIGHT: Post-PPCI Anticoagulation in STEMI Patients
-
6m 1sPart 4 | Session 24 ARAMIS: Anakinra versus Placebo in Acute Myocarditis
-
4m 9s
-
6m 42sPart 5 | Session 1 Takeaways from ESC 2023 with Dr Cvijic & Dr Grapsa
-
9m 47sPart 5 | Session 2 Takeaways from ESC 2023 with Dr Al-Lamee, Dr Colleran & Dr Paradies
-
3m 33sPart 6 | Session 1 Leadership in Guidelines and Cardiovascular Education with Dr Robert Byrne
-
59sPart 6 | Session 2 Patient Care and Treatment Strategies with Dr Myeong-Ki Hong
-
2m 2s
-
1m 27sPart 6 | Session 4 Intersection of Politics and Medicine with Dr Luengo-Fernandez
-
1m 24sPart 6 | Session 5 Choosing Cardiology and Advice to Researchers with Dr Robert Mentz
-
1m 10sPart 6 | Session 6 Leadership in the Context of Clinical Trials with Dr Michelle O'Donoghue
-
46sPart 6 | Session 7 Trials to Watch Out For with Dr Masahiro Natsuaki
-
49s
-
1m 2sPart 6 | Session 9 Emerging Topics in Electrophysiology with Dr Tobias Reichlin
-
1m 23sPart 6 | Session 10 Key Trials and Data from ESC 23 with Dr Ziad Ali
-
36s
-
58sPart 6 | Session 12 Inspiring Teams with Prof Barbara Stahli
-
2m 21sPart 6 | Session 13 Advice for Early-Career Researchers from Dr Gregg Stone
-
48sPart 6 | Session 14 New Technologies in Electrophysiology with Dr Mads Brix Kronborg
-
1m 25sPart 6 | Session 15 Considering Unmet Needs in Patient Care with Dr Duk-Woo Park
-
59sPart 6 | Session 16 Improving Clinical Practice with Dr Do-Yoon Kang
-
1m 28sPart 6 | Session 17 Contributing to the Guidelines with Dr Jozine Ter Maaten
-
2m 41sPart 6 | Session 18 Emerging Trends in Amyloidosis with Prof Julian Gillmore
-
30sPart 6 | Session 19 Working With Role Models with Dr Yan Yan
-
1m 17sPart 6 | Session 20 The Importance of Mentorship with Dr Giles Montalescot
-
1m 24sPart 6 | Session 21 Personalised Medicine & Team Approach With Dr Christian Sohns
-
1m 51sPart 6 | Session 22 Advancement of EP & Adapting New Approaches With Dr Philipp Sommer
-
2m 14s
-
47m 55sPart 1 | Session 1 ESC 23 Late-breaking Science Wrap Up
-
28m 31sPart 1 | Session 2 ESC 23 Late-breaking Science Preview
-
13m 31sPart 2 | Session 1 The ECLS-Shock Trial
-
13m 24sPart 2 | Session 2 The STEP HFpEF Trial
-
9m 37sPart 2 | Session 3 The RECORD MI Registry
-
30m 23sPart 2 | Session 4 Heart Failure at ESC 2023: Recapitulations, Postulations, Predictions
-
13m 28sPart 3 | Session 1 Day 1 Highlights: New Guidelines, STEP-HFpEF, COP-AF
-
16m 34sPart 3 | Session 2 Day 2 Highlights: BUDAPEST-CRT, FIRE, ECLS-Shock, STOPDAPT-3
-
13m 51sPart 3 | Session 3 Day 3 Highlights: OCT Trials, MULTISTARS-AMI, ATTRibute-CM
-
8m 3sPart 3 | Session 4 Day 4 Highlights: OPT-BIRISK & NITRATE-CIN
-
6m 46sPart 4 | Session 1 New Guidelines For the Management of Acute Coronary Syndromes
-
3m 42sPart 4 | Session 2 NOAH-AFNET 6: Oral Anticoagulation in Pts With AHRE
-
3m 42sPart 4 | Session 3 LODESTAR: Rosuvastatin Vs Atorvastatin Treatment For CAD Patients
-
6m 14sPart 4 | Session 4 Economic Burden of Cardiovascular Disease in the EU
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose (NCT05581303) in this succinct interview.
OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered subcutaneously as compared to placebo in patients with atherosclerotic cardiovascular disease and elevated Lipoprotein(a).
In results revealed at AHA 2022, the trial showed that when dosed at 75mg or higher every 12 weeks, olpasiran reduced Lp(a) concentration by more than 95% in patients with atherosclerotic cardiovascular disease, and the treatment to be safe and well-tolerated.
This trial update from ESC 2023 investigated an off-treatment period in the same patient group. This late-breaking update revealed that patients treated with a higher dose of olpasiran had a 40-50% reduction in LP(a) up to a year after their last dose.
Questions:
- What do we know about the role of Lp(a)? What are the available treatments for addressing Lp(a) concentrations?
- What question does this extension study aim to address?
- What was the study design and eligibility criteria?
- What are the key findings presented at ESC?
- What are the take-home messages?
- What are the remaining questions? What are the next steps?
Recorded on-site at ESC Congress 2023, Amsterdam.
Editors: Mirjam Boros and Jordan Rance
Video Specialists: Dan Brent, Tom Green, Mike Knight, Oliver Miles
What's hot at the European Society of Cardiology (ESC) Congress 2023?
Browse our curated coverage of the latest updates in cardiology from Amsterdam.
- Watch our View From the Thoraxcenter series for a concise line up of the most awaited trials from Prof Nicolas Van Mieghem and Dr Joost Daemen.
- For a deeper dive into key clinical trial data and its applicability, host, Dr Harriette Van Spall meets with Principal Investigators in her Late-Breaker Discussion series.
- View a condensed summary of the crucial takeaways from each day in our Wrap-Up series with Dr Mirvat Alasnag.
- Our short, accessible Expert Interviews with select faculty focus on data, patient care and the future of their field.
- We will feature personal perspective in Behind the Heart series focusing on career pathways, personal motivations and perspectives on the field.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussions with Dr Harriette Van Spall
Part 3
Daily Wrap-Ups with Dr Alasnag & Dr Al-Shaibi
Part 4
Expert Interviews
Part 5
Women as One & Radcliffe Cardiology Presents
Faculty Biographies
Michelle O'Donoghue
Associate Physician
Dr Michelle O’Donoghue, is an Associate Physician in the Cardiology Division of Brigham and Women’s Hospital, an Affiliate Physician in the Cardiology Division of Massachusetts General Hospital and an Assistant Professor in Medicine at Harvard Medical School in Boston, Massachusetts, US. She is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, founded by Dr Eugene Braunwald.
Dr O’Donoghue’s primary research focus is the design and conduct of multicentre clinical trials for patients with stable and unstable heart disease. Additional clinical research interests include the evaluation of novel antiplatelet drugs, established and novel biomarkers, the study of women and heart disease and the development of novel therapeutics in the management of acute coronary syndromes.
Comments